Major depression disorder - etiology and treatment
DOI:
https://doi.org/10.12775/JEHS.2023.37.01.008Keywords
major depression disorder, microbiota, esketamineAbstract
Introduction and purpose: The problem of major depression disorder (MDD) affects more and more people. In a few years, it may become the most common disease after cardiovascular diseases and cancer. MDD are manifested by a depressed mood, decreased energy, loss of interest and the ability to enjoy life, as well as a number of other additional symptoms. Untreated MDD can lead to disability. This entails not only consequences for the sick person but also increased social costs. That is why it is so important to know the causes of its formation and to look for new therapeutic methods.
State of knowledge: The development of MDD is influenced by genetic factors, inflammatory factors and hormonal disorders, changes in the structure of the brain, disorders in neurotransmission. The microbiome-gut-brain axis affects mood regulation and neurotransmission in the brain. Bacteria such as Escherichia, Shigella, Enterococcus, Streptococccus, Alistipes, Parabacterioides, Veillonella have been identified as having a potential negative effect on the development of MDD and response to treatment. The use of probiotics containing Lactobacillus helveticus R0052, Bifidobacterium longum and Clostridium butyricum MIYAIRI 588 may help reduce the symptoms of MDD. In recent years, the US Food and Drug Administration (FDA) has approved the intranasal preparation of esketamine for the treatment of treatment-resistant depression and major depressive disorder with severe suicidal thoughts. Unlike other antidepressants, it has a quick effect on reducing symptoms.
Summary: Due to the global problem of MDD, further research is needed to better understand the mechanisms of its formation. Particular attention should be paid to the influence of microbiota.
References
Gałacki P, Szulc A. Psychiatria. Edycja 1. Wrocław: Edra Urban&Partner; 2018.
Pełka-Wysiecka J, Samochowiec J. Depression — differentiated pharmacotheraphy indeed? Psychiatria. 2014;11(3):141-147.
WHO. Depressive disorder (depression). https://www.who.int/news-room/fact-sheets/detail/depression (accessed on 27 April 2023)
Huang R, Wang K, Hu J. Effect of Probiotics on Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2016;8(8):483. doi: 10.3390/nu8080483
Paris J. The Mistreatment of Major Depressive Disorder. Can J Psychiatry. 2014;59(3):148–151. doi: 10.1177/070674371405900306
Chrițá AL, Gheorman V,Ondari DB, Oguveanu IR. Current understanding of the neurobiology of major depressive disorder. Rom J Morphol Embryol 2015;56(2):651-658.
Menard C, Hodes GE, Russo SJ. Pathogenesis of depression: insights from human and rodent studies. Neuroscience. 2016;321:138-162.
doi: 10.1016/j.neuroscience.2015.05.053
Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 2012;35(1):47-56. doi: 10.1016/j.tins.2011.11.004
Zhang HF, Mellor D, Peng DH. Neuroimaging genomic studies in major depressive disorder: A systematic review. CNS Neurosci Ther. 2018;24(11):1020-1036.
doi: 10.1111/cns.12829
Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet. 2012;379(9820):1045-55.
doi: 10.1016/S0140-6736(11)60602-8
Li Z, Ruan M, Chen J, Fang Y. Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications. Neurosci Bull. 2021;37(6):863-880. doi: 10.1007/s12264-021-00638-3.
Kennis M, Gerritsen L, van Dalen M, Williams A, Cuijpers P, Bockting C. Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2020;25(2):321-338. doi: 10.1038/s41380-019-0585-z
Boku S, Nakagawa S, Toda H, Hishimoto A. Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry Clin. Neurosci. 2018;72:3-12.
doi: 10.1111/pcn.12604
Yang L, Zhao Y, Wang Y, Liu L, Zhang X, Li B, Cui R. The Effects of Psychological Stress on Depression. Curr Neuropharmacol. 2015;13(4):494-504.
doi: 10.2174/1570159x1304150831150507
Kennedy SH, Ceniti AK. Unpacking Major Depressive Disorder: From Classification to Treatment Selection. Can J Psychiatry. 2018;63(5):308-313.
doi: 10.1177/0706743717748883
Syed SA, Beurel E, Loewenstein DA, Lowell JA, Craighead WE, Dunlop BW, et al. Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response. Neuron. 2018;99(5):914-924.e3
doi: 10.1016/j.neuron.2018.08.001
Chourbaji S, Urani A, Inta I, Sanchis-Segura C, Brandwein C, Zink M, et al. IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiol Dis. 2006;23(3):587-94.
doi: 10.1016/j.nbd.2006.05.001
Li Z, Qi D, Chen J, Zhang C, Yi Z, Yuan C, et al. Venlafaxine inhibits the upregulation of plasma tumor necrosis factor-alpha (TNF-α) in the Chinese patients with major depressive disorder: a prospective longitudinal study. Psychoneuroendocrinology. 2013;38(1):107-114.
doi: 10.1016/j.psyneuen.2012.05.005
Kang SG, Cho SE. Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder. Int J Mol Sci. 2020;21(6):2148.
doi: 10.3390/ijms21062148
Bartlett EA, DeLorenzo C, Sharma P, Yang J, Zhang M, Petkova E,et al. Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. Neuropsychopharmacology. 2018;43(11):2221-2230. doi: 10.1038/s41386-018-0122-9
Gray JP, Müller VI, Eickhoff SB, Fox PT. Multimodal Abnormalities of Brain Structure and Function in Major Depressive Disorder: A Meta-Analysis of Neuroimaging Studies. Am J Psychiatry. 2020;177(5):422-434.
doi: 10.1176/appi.ajp.2019.19050560
De Crescenzo F, Ciliberto M, Menghini D, Treglia G, Ebmeier KP, Janiri L. Is 18F-FDG-PET suitable to predict clinical response to the treatment of geriatric depression? A systematic review of PET studies. Aging Ment Health. 2017;21(9):889-894. doi: 10.1080/13607863.2016.1247413
Rajkowska G, O'Dwyer G, Teleki Z, Stockmeier CA, Miguel-Hidalgo JJ. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology. 2007;32(2):471-82.
doi: 10.1038/sj.npp.1301234
Youssef MM, Underwood MD, Huang YY, Hsiung SC, Liu Y, Simpson NR,et al. Association of BDNF Val66Met Polymorphism and Brain BDNF Levels with Major Depression and Suicide. Int J Neuropsychopharmacol. 2018;21(6):528-538. doi: 10.1093/ijnp/pyy008
Duric V, Banasr M, Licznerski P, Schmidt HD, Stockmeier CA, Simen AA, et al. A negative regulator of MAP kinase causes depressive behavior. Nat Med. 2010;16(11):1328-32. doi: 10.1038/nm.2219
McGuinness AJ, Davis JA, Dawson SL, Loughman A, Collier F, O'Hely M, et al. A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. Mol Psychiatry. 2022;27(4):1920-1935. doi: 10.1038/s41380-022-01456-3
Zhuang Z, Yang R, Wang W, Qi L, Huang T. Associations between gut microbiota and Alzheimer's disease, major depressive disorder, and schizophrenia. J Neuroinflammation. 2020;17(1):288. doi: 10.1186/s12974-020-01961-8
Knuesel T, Mohajeri MH. The Role of the Gut Microbiota in the Development and Progression of Major Depressive and Bipolar Disorder. Nutrients. 2021;14(1):37.
doi: 10.3390/nu14010037
Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015;48:186-94. doi: 10.1016/j.bbi.2015.03.016.
Maes M, Kubera M, Leunis JC, Berk M. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord. 2012;141(1):55-62.
doi: 10.1016/j.jad.2012.02.023
Rudzki L, Ostrowska L, Pawlak D, Małus A, Pawlak K, Waszkiewicz N, Szulc A. Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study. Psychoneuroendocrinology. 2019;100:213-222.
doi: 10.1016/j.psyneuen.2018.10.010
Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011;105(5):755-64. doi: 10.1017/S0007114510004319
Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, Jafari P, Akbari H, Taghizadeh M, et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Nutrition. 2016 Mar;32(3):315-20.
doi: 10.1016/j.nut.2015.09.003
Miyaoka T, Kanayama M, Wake R, Hashioka S, Hayashida M, Nagahama M, et al. Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial. Clin Neuropharmacol. 2018;41(5):151-155. doi: 10.1097/wnf.0000000000000299
Nishida K, Sawada D, Kuwano Y, Tanaka H, Rokutan K. Health Benefits of Lactobacillus gasseri CP2305 Tablets in Young Adults Exposed to Chronic Stress: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients. 2019;11(8):1859.
doi: 10.3390/nu11081859
Sawada D, Kuwano Y, Tanaka H, Hara S, Uchiyama Y, SugawaraT, et al. Daily intake of Lactobacillus gasseri CP2305 relieves fatigue and stress-related symptoms in male university Ekiden runners: A double-blind, randomized, and placebo-controlled clinical trial. Journal of Functional Foods. 2019;57:465-476. doi:10.1016/j.jff.2019.04.022
Psiuk D, Nowak EM, Dycha N, Łopuszańska U, Kurzepa J, Samardakiewicz M. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. Int J Mol Sci. 2022;23(19):11450.
doi: 10.3390/ijms231911450
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry. 2021;178(5):383-399. doi: 10.1176/appi.ajp.2020.20081251
U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified (Accessed on 27 April 2023)
Sattar Y, Wilson J, Khan AM, Adnan M, Azzopardi Larios D, Shrestha S, et al. A Review of the Mechanism of Antagonism of N-methyl-D-aspartate Receptor by Ketamine in Treatment-resistant Depression. Cureus. 2018;10(5):e2652. doi: 10.7759/cureus.2652
Williams NR, Heifets BD, Bentzley BS, Blasey C, Sudheimer KD, Hawkins J, et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol Psychiatry. 2019;24(12):1779-1786.
doi: 10.1038/s41380-019-0503-4
Witt K, Potts J, Hubers A. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. Australian & New Zealand Journal of Psychiatry. 2020;54(1):29-45.
doi: 10.1177/0004867419883341
Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(9):893-903. doi: 10.1001/jamapsychiatry.2019.1189
Jalloh M. Esketamine (Spravato) for Treatment-Resistant Depression. Am Fam Physician. 2020;101(6):339-340.
Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(2):139-148.
doi: 10.1001/jamapsychiatry.2017.3739
Doherty T, Wajs E, Melkote R, Miller J, Singh JB, Weber MA. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program. CNS Drugs. 2020;34(3):299-310.
doi: 10.1007/s40263-020-00699-4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Paulina Czuchryta, Rafał Babiak, Karolina Bajak, Anastazja Domańska, Agnieszka Gawęda, Agata Grabek, Julia Rutkowska, Żaneta Rzęsa-Tokarczyk, Klaudia Skorek, Agnieszka Urbańczyk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 1041
Number of citations: 0
